This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck Ends Development of Two Experimental Cancer Drugs
by Zacks Equity Research
MRK's decision to discontinue the development of two cancer drugs follows a series of setbacks in multiple late-stage studies.
CHMP Endorses Merck's Kidney Cancer Drug for Two Indications
by Zacks Equity Research
The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated with renal cell carcinoma.
Merck (MRK) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Merck (MRK) reachead $101.25 at the closing of the latest trading day, reflecting a +1.5% change compared to its last close.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Merck (MRK) closed at $99.75 in the latest trading session, marking a -1.24% move from the prior day.
The Zacks Analyst Blog Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International
by Zacks Equity Research
Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International are included in this Analyst Blog.
Top Analyst Reports for Alphabet, Oracle & Merck
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Oracle Corporation (ORCL) and Merck & Co., Inc. (MRK), as well as two micro-cap stocks, Canterbury Park Holding Corporation (CPHC) and CompX International Inc. (CIX).
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study
by Zacks Equity Research
The KEYLYNK-001 study evaluating Merck's Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary goal in epithelial ovarian cancer.
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to AstraZeneca and Daiichi Sankyo's Dato-DXd for previously treated advanced EGFR-mutated NSCLC.
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday
by Zacks Equity Research
SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company's lead pipeline drug.
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ
by Kinjel Shah
LLY's Zepbound shows better weight loss than NVO's Wegovy in a study. FDA updates for MRK, RHHBY, JNJ and AZN drugs grab headlines.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC
by Zacks Equity Research
This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
by Zacks Equity Research
GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids
by Zacks Equity Research
J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
by Zacks Equity Research
Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis are included in this Analyst Blog.
Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success
by Kinjel Shah
RHHBY is set to acquire Poseida. MRK and AZN's late-stage studies for expanded use of new drugs meet their respective goals.
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?
by Zacks Equity Research
GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
by Zacks Equity Research
The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025.
Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study
by Zacks Equity Research
MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.
Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?
by Zacks Equity Research
EXEL's shares move north 25% in a month on the back of strong third-quarter results and raised outlook. We are optimistic about the stock as we believe there is room for growth.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Zacks Analyst Blog Highlights Broadcom, Merck, Qualcomm and Natural Health
by Zacks Equity Research
Broadcom, Merck, Qualcomm and Natural Health are included in this Analyst Blog.
Top Analyst Reports for Broadcom, Merck & Qualcomm
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co. (MRK) and Qualcomm (QCOM), as well as a micro-cap stock, Natural Health Trends Corp. (NHTC).
Merck Stock Trades Near 52-Week Low: What's Next for Investors?
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
by Zacks Equity Research
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.